Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 for allergic conditions like asthma.
Eli Lilly is further strengthening its position in immunology with its 13th acquisition of the year, paying up to $2.875 billion for
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions
The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that…
Empresa informou que a Merida está desenvolvendo uma nova classe de terapias de precisão para graves doenças autoimunes e…
Eli Lilly adquire Merida, que desenvolve tratamento contra doença de Graves
Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious…
Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs &…
Eli Lilly compra empresa de biotecnologia Merida Biosciences por até US$ 2,87 bi
